Эндоваскулярная окклюзия ушка левого предсердия при фибрилляции предсердий: современные представления и перспективы (обзор)

Эндоваскулярная окклюзия ушка левого предсердия при фибрилляции предсердий: современные представления и перспективы (обзор)

Автор: Канорский С. Г.

Журнал: Сибирский журнал клинической и экспериментальной медицины @cardiotomsk

Рубрика: Обзоры и лекции

Статья в выпуске: 4 т.38, 2023 года.

Бесплатный доступ

Несмотря на все более широкое применение эндоваскулярной окклюзии ушка левого предсердия (ЭОУЛП) в практике лечения пациентов с фибрилляцией предсердий (ФП), выбор оптимальной тактики выполнения процедуры, особенно последующей антитромботической терапии, остается малоизученным. Настоящий обзор проведен с целью критической оценки современных представлений о безопасности и эффективности ЭОУЛП при ФП. Обсуждены результаты важнейших клинических исследований ЭОУЛП у пациентов с ФП, положения действующих клинических рекомендаций по проведению этой процедуры. Рассмотрены доступные данные о возможностях антитромботической терапии после ЭОУЛП, перспективы будущих исследований в устранении пробелов в доказательной базе данной методики.

Еще

Фибрилляция предсердий, ушко левого предсердия, эндоваскулярная окклюзия ушка левого предсердия, пероральная антикоагулянтная терапия, антитромбоцитарная терапия, тромбообразование на устройстве

Короткий адрес: https://sciup.org/149144442

IDR: 149144442   |   DOI: 10.29001/2073-8552-2023-38-4-46-54

Список литературы Эндоваскулярная окклюзия ушка левого предсердия при фибрилляции предсердий: современные представления и перспективы (обзор)

  • Elliott A.D., Middeldorp M.E., Van Gelder I.C., Albert C.M., Sanders P. Epidemiology and modifiable risk factors for atrial fibrillation. Nat. Rev. Cardiol. 2023;20(6):404-417. https://doi.org/10.1038/s41569-022-00820-8.
  • Escudero-Martínez I., Morales-Caba L., Segura T. Atrial fibrillation and stroke: A review and new insights. Trends Cardiovasc. Med. 2023;33(1):23-29. https://doi.org/10.1016/j.tcm.2021.12.001.
  • Hindricks G., Potpara T., Dagres N., Arbelo E., Bax J.J., Blomström-Lundqvist C. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur. Heart J. 2021;42(5):373-498. https://doi.org/10.1093/eurheartj/ehaa612.
  • Saw J., Holmes D.R., Cavalcante J.L., Freeman J.V., Goldsweig A.M., Kavinsky C.J. et al. SCAI/HRS expert consensus statement on transcatheter left atrial appendage closure. Heart Rhythm. 2023;20(5):e1- e16. https://doi.org/10.1016/j.hrthm.2023.01.007.
  • Glikson M., Wolff R., Hindricks G., Mandrola J., Camm A.J., Lip G.Y.H. et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion an update. Europace. 2020;22(2):184. https://doi.org/10.1093/europace/euz258.
  • January C.T., Wann L.S., Calkins H., Chen L.Y., Cigarroa J.E., Cleveland J.C.Jr. et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ ACC/HRS Guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019;140(2):e125-e151. https://doi.org/10.1161/CIR.0000000000000665.
  • Whitlock R.P., Belley-Cote E.P., Paparella D., Healey J.S., Brady K., Sharma M. et al. Left atrial appendage occlusion during cardiac surgery to prevent stroke. N. Engl. J. Med. 2021;384(22):2081-2091. https://doi.org/10.1056/NEJMoa2101897.
  • Reddy V.Y., Sievert H., Halperin J., Doshi S.K., Buchbinder M., Neuzil P. et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA. 2014;312(19):1988-1998. https://doi.org/10.1001/jama.2014.15192.
  • Holmes D.R.Jr., Kar S., Price M.J., Whisenant B., Sievert H., Doshi S.K. et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J. Am. Coll. Cardiol. 2014;64(1):1-12. https://doi.org/10.1016/j.jacc.2014.04.029.
  • Reddy V.Y., Doshi S.K., Kar S., Gibson D.N., Price M.J., Huber K. et al. 5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J. Am. Coll. Cardiol. 2017;70(24):2964-2975. https://doi.org/10.1016/j.jacc.2017.10.021.
  • Boersma L.V., Ince H., Kische S., Pokushalov E., Schmitz T., Schmidt B. et al. Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial. Heart Rhythm. 2017;14(9):1302-1308. https://doi.org/10.1016/j.hrthm.2017.05.038.
  • Berti S., Santoro G., Brscic E., Montorfano M., Vignali L., Danna P. et al. Left atrial appendage closure using AMPLATZER™ devices: A large, multicenter, Italian registry. Int. J. Cardiol. 2017;248:103-107. https://doi.org/10.1016/j.ijcard.2017.07.052.
  • Landmesser U., Tondo C., Camm J., Diener H.C., Paul V., Schmidt B. et al. Left atrial appendage occlusion with the AMPLATZER Amulet device: one-year follow-up from the prospective global Amulet observational registry. EuroIntervention. 2018;14(5):e590-e597. https://doi.org/10.4244/EIJ-D-18-00344.
  • Osmancik P., Herman D., Neuzil P., Hala P., Taborsky M., Kala P. et al. 4-year outcomes after left atrial appendage closure versus nonwarfarin oral anticoagulation for atrial fibrillation. J. Am. Coll. Cardiol. 2022;79(1):1-14. https://doi.org/10.1016/j.jacc.2021.10.023.
  • Busu T., Khan S.U., Alhajji M., Alqahtani F., Holmes D.R., Alkhouli M. Observed versus expected ischemic and bleeding events following left atrial appendage occlusion. Am. J. Cardiol. 2020;125(11):1644-1650. https://doi.org/10.1016/j.amjcard.2020.02.041.
  • Alkhouli M., Friedman P.A. ischemic stroke risk in patients with nonvalvular atrial fibrillation: JACC review topic of the week. J. Am. Coll. Cardiol. 2019;74(24):3050-3065. https://doi.org/10.1016/j.jacc.2019.10.040.
  • Lakkireddy D., Thaler D., Ellis C.R., Swarup V., Sondergaard L., Carroll J. et al. Amplatzer Amulet left atrial appendage occluder versus Watchman device for stroke prophylaxis (Amulet IDE): A randomized, controlled trial. Circulation. 2021;144(19):1543-1552. https://doi.org/10.1161/CIRCULATIONAHA.121.057063.
  • Dukkipati S.R., Kar S., Holmes D.R., Doshi S.K., Swarup V., Gibson D.N. et al. Device-related thrombus after left atrial appendage closure: incidence, predictors, and outcomes. Circulation. 2018;138(9):874-885. https://doi.org/10.1161/CIRCULATIONAHA.118.035090.
  • Alkhouli M., Busu T., Shah K., Osman M., Alqahtani F., Raybuck B. Incidence and clinical impact of device-related thrombus following percutaneous left atrial appendage occlusion: a meta-analysis. JACC Clin. Electrophysiol. 2018;4(12):1629-1637. https://doi.org/10.1016/j.jacep.2018.09.007.
  • Kar S., Doshi S.K., Sadhu A., Horton R., Osorio J., Ellis C. et al. Primary Outcome evaluation of a next-generation left atrial appendage closure device: results from the PINNACLE FLX trial. Circulation. 2021;143(18):1754-1762. https://doi.org/10.1161/CIRCULATIONAHA.120.050117.
  • Simard T., Jung R.G., Lehenbauer K., Piayda K., Pracoń R., Jackson G.G. et al. Predictors of device-related thrombus following percutaneous left atrial appendage occlusion. J. Am. Coll. Cardiol. 2021;78(4):297-313. https://doi.org/10.1016/j.jacc.2021.04.098.
  • Sedaghat A., Vij V., Al-Kassou B., Gloekler S., Galea R., Fürholz M. et al. Device-related thrombus after left atrial appendage closure: data on thrombus characteristics, treatment strategies, and clinical outcomes from the EUROC-DRT-Registry. Circ. Cardiovasc. Interv. 2021;14(5):e010195. https://doi.org/10.1161/CIRCINTERVENTIONS.120.010195.
  • Simard T.J., Hibbert B., Alkhouli M.A., Abraham N.S., Holmes D.R.Jr. Device-related thrombus following left atrial appendage occlusion. EuroIntervention. 2022;18(3):224-232. https://doi.org/10.4244/EIJ-D-21-01010.
  • Asmarats L., Cruz-González I., Nombela-Franco L., Arzamendi D., Peral V., Nietlispach F. et al. recurrence of device-related thrombus after percutaneous left atrial appendage closure. Circulation. 2019;140(17):1441-1443. https://doi.org/10.1161/CIRCULATIONAHA.119.040860.
  • Tan B.E., Boppana L.K.T., Abdullah A.S., Chuprun D., Shah A., Rao M. et al. Safety and feasibility of same-day discharge after left atrial appendage closure with the WATCHMAN device. Circ. Cardiovasc. Interv. 2021;14(1):e009669. https://doi.org/10.1161/CIRCINTERVENTIONS.120.009669.
  • Saw J., Nielsen-Kudsk J.E., Bergmann M., Daniels M.J., Tzikas A., Reisman M. et al. Antithrombotic therapy and device-related thrombosis following endovascular left atrial appendage closure. JACC Cardiovasc. Interv. 2019;12(11):1067-1076. https://doi.org/10.1016/j.jcin.2018.11.001.
  • Saliba W.I., Kawai K., Sato Y., Kopesky E., Cheng Q., Ghosh S.K.B. et al. Enhanced thromboresistance and endothelialization of a novel fluoropolymer-coated left atrial appendage closure device. JACC Clin. Electrophysiol. 2023;9(8Pt2):1555-1567. https://doi.org/10.1016/j.jacep.2023.04.013.
  • Tan B.E., Wong P.Y., Lee J.Z., Tan N.Y., Rao M., Cheung J.W. Direct oral anticoagulant versus warfarin after left atrial appendage closure with WATCHMAN: updated systematic review and meta-analysis. Curr. Probl. Cardiol. 2022;47(11):101335. https://doi.org/10.1016/j.cpcardiol.2022.101335.
  • Patti G., Pengo V., Marcucci R., Cirillo P., Renda G., Santilli F. et al. The left atrial appendage: from embryology to prevention of thromboembolism. Eur. Heart J. 2017;38(12):877-887. https://doi.org/10.1093/eurheartj/ehw159.
  • Hildick-Smith D., Landmesser U., Camm A.J., Diener H.C., Paul V., Schmidt B. et al. Left atrial appendage occlusion with the Amplatzer™ Amulet™ device: full results of the prospective global observational study. Eur. Heart J. 2020;41(30):2894-2901. https://doi.org/10.1093/eurheartj/ehaa169.
  • Landmesser U., Tondo C., Camm J., Diener H.C., Paul V., Schmidt B. et al. Left atrial appendage occlusion with the AMPLATZER Amulet device: one-year follow-up from the prospective global Amulet observational registry. EuroIntervention. 2018;14(5):e590-e597. https://doi.org/10.4244/EIJ-D-18-00344.
  • Bergmann M.W., Ince H., Kische S., Schmitz T., Meincke F., Schmidt B. et al. Real-world safety and efficacy of WATCHMAN LAA closure at one year in patients on dual antiplatelet therapy: results of the DAPT subgroup from the EWOLUTION all-comers study. EuroIntervention. 2018;13(17):2003-2011. https://doi.org/10.4244/EIJ-D-17-00672.
  • Duthoit G., Silvain J., Marijon E., Ducrocq G., Lepillier A., Frere C. et al. Circ. Cardiovasc. Interv. 2020;13(7):e008481. https://doi.org/10.1161/CIRCINTERVENTIONS.119.008481.
  • Whitlock R.P., Belley-Cote E.P., Paparella D., Healey J.S., Brady K., Sharma M. et al. Left atrial appendage occlusion during cardiac surgery to prevent stroke. N. Engl. J. Med. 2021;384(22):2081-2091. https://doi.org/10.1056/NEJMoa2101897.
  • Della Rocca D.G., Magnocavallo M., Di Biase L., Mohanty S., Trivedi C., Tarantino N. et al. Half-dose direct oral anticoagulation versus standard antithrombotic therapy after left atrial appendage occlusion. JACC Cardiovasc. Interv. 2021;14(21):2353-2364. https://doi.org/10.1016/j.jcin.2021.07.031.
  • Li X., Zhang X., Jin Q., Xue Y., Lu W., Ge J. et al. clinical efficacy and safety comparison of rivaroxaban and dabigatran for nonvalvular atri al fibrillation patients undergoing percutaneous left atrial appendage closure operation. Front. Pharmacol. 2021;12:614762. https://doi.org/10.3389/fphar.2021.614762.
  • Patti G., Sticchi A., Verolino G., Pasceri V., Vizzi V., Brscic E. et al. Safety and efficacy of single versus dual antiplatelet therapy after left atrial appendage occlusion. Am. J. Cardiol. 2020;134:83-90. https://doi.org/10.1016/j.amjcard.2020.08.013.
  • Patti G., Ghiglieno C. Indications, evidence, and controversy in the closure of the left atrial appendage. Eur. Heart J. Suppl. 2023;25(Suppl. B):B126-B130. https://doi.org/10.1093/eurheartjsupp/suad091.
  • Bing S., Chen R.R. Clinical efficacy and safety comparison of Watchman device versus ACP/Amulet device for percutaneous left atrial appendage closure in patients with nonvalvular atrial fibrillation: A study-level meta-analysis of clinical trials. Clin. Cardiol. 2023;46(2):117-125. https://doi.org/10.1002/clc.23956.
  • Lakkireddy D., Thaler D., Ellis C.R., Swarup V., Gambhir A., Hermiller J. et al. 3-year outcomes from the amplatzer Amulet left atrial appendage occluder randomized controlled trial (Amulet IDE). JACC Cardiovasc Interv. 2023;16(15):1902-1913. https://doi.org/10.1016/j.jcin.2023.06.022.
Еще
Статья обзорная
SciUp 2024 © 2024 ©